PMID- 33262635
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1178-7066 (Print)
IS  - 1178-7066 (Electronic)
IS  - 1178-7066 (Linking)
VI  - 13
DP  - 2020
TI  - Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to 
      Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by 
      Type 2 Diabetes Mellitus?
PG  - 645-653
LID - 10.2147/PGPM.S279719 [doi]
AB  - BACKGROUND: There have been few studies on CYP2C19 genotypes and clopidogrel 
      response associated with ischemic stroke (IS), especially IS complicated by type 
      2 diabetes mellitus (T2DM). This study aimed to investigate the possible 
      association between CYP2C19 polymorphisms and high on-treatment platelet 
      reactivity (HTPR) in IS patients with T2DM in China. PATIENTS AND METHODS: A 
      total of 426 consecutive IS patients with T2DM were enrolled in this case-control 
      study and they were divided into HTPR group and non-HTPR group according to the 
      ADP-induced platelet inhibition (PIADP) assessed by thromboelastography (TEG). 
      Genotypes were detected by polymerase chain reaction-restriction fragment length 
      polymorphism (PCR-RFLP) method. Various clinical and demographic data were also 
      recorded. The association between CYP2C19 genetic variants and platelet function 
      was assessed. RESULTS: Carriers of CYP2C19*2 heterozygous and mutant homozygous 
      genotypes showed significantly lower PIADP than non-carriers (27.2% vs 38.3%, p < 
      0.001; 27.41% vs 38.3%, p = 0.012, respectively). Compared with the control 
      group, the CYP2C19*2 A allele was more frequent in the HTPR group (34.51% vs 
      25.82%, p = 0.002). The carriage of CYP2C19*2 mutant allele was significantly 
      associated with increased risk of HTPR (odds ratio (OR) = 1.94, 95% confidence 
      interval (CI) = 1.32-2.85). There was no significant correlation between 
      CYP2C19*3 or *17 genotypes and HTPR risk. CONCLUSION: CYP2C19*2 mutant allele was 
      associated with attenuated platelet response to clopidogrel and increased risk of 
      HTPR in IS patients with T2DM, suggesting that CYP2C19*2 polymorphism might be an 
      important predictor of HTPR in this high-risk population.
CI  - (c) 2020 Sun et al.
FAU - Sun, Jialin
AU  - Sun J
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Leng, Ping
AU  - Leng P
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Sun, Chen
AU  - Sun C
AD  - Department of Pharmacy, Qingdao Municipal Hospital, Qingdao 266003, Shandong, 
      People's Republic of China.
FAU - Xu, Wen
AU  - Xu W
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Zhao, Zhenhuan
AU  - Zhao Z
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Li, Xiao
AU  - Li X
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Zhang, Xiaolei
AU  - Zhang X
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 
      266003, Shandong, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - New Zealand
TA  - Pharmgenomics Pers Med
JT  - Pharmacogenomics and personalized medicine
JID - 101514107
PMC - PMC7698285
OTO - NOTNLM
OT  - CYP2C19
OT  - clopidogrel
OT  - high on-treatment platelet reactivity
OT  - ischemic stroke
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/12/03 06:00
MHDA- 2020/12/03 06:01
PMCR- 2020/11/23
CRDT- 2020/12/02 05:32
PHST- 2020/09/08 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/12/02 05:32 [entrez]
PHST- 2020/12/03 06:00 [pubmed]
PHST- 2020/12/03 06:01 [medline]
PHST- 2020/11/23 00:00 [pmc-release]
AID - 279719 [pii]
AID - 10.2147/PGPM.S279719 [doi]
PST - epublish
SO  - Pharmgenomics Pers Med. 2020 Nov 23;13:645-653. doi: 10.2147/PGPM.S279719. 
      eCollection 2020.